Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1422631 | 0.95 | BTK (0.47) | BTKCD69 | |
| SCHEMBL1422848 | 0.90 | BTK (0.48) | BTKCD69 | |
| SCHEMBL1422466 | 0.89 | BTK (0.55) | BTK | |
| SCHEMBL12651422 | 0.88 | BTK (0.57) | BTKCD69 | |
| SCHEMBL1422629 | 0.88 | BTK (0.44) | BTK | |
| SCHEMBL12651118 | 0.87 | BTK (0.56) | BTK | |
| SCHEMBL1422569 | 0.86 | BTK (0.56) | BTK | |
| SCHEMBL12651333 | 0.85 | BTK (0.57) | BTKCD69 | |
| SCHEMBL1422577 | 0.85 | BTK (0.43) | BTK | |
| SCHEMBL1422735 | 0.81 | BTK (0.52) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2297105-B1 | SUBSTITUTED AMIDES, METHOD OF MAKING, AND USE AS BTK INHIBITORS | GILEAD CONNECTICUT INC (US) | 2015-09-02 | — | — | EP | claimed |
| US-8426424-B2 | Certain substituted amides, method of making, and method of use thereof | CGI PHARMACEUTICALS, INC. (US) | 2013-04-23 | — | — | US | claimed |
| US-20110118233-A1 | Certain Substituted Amides, Method of Making, and Method of Use Thereof | CGI PHARMACEUTICALS, INC. | 2011-05-19 | — | — | US | claimed |
| EP-2297105-A1 | SUBSTITUTED AMIDES, METHOD OF MAKING, AND USE AS BTK INHIBITORS | CGI Pharmaceuticals, Inc. (US) | 2011-03-23 | — | — | EP | claimed |
| WO-2009137596-A1 | SUBSTITUTED AMIDES, METHOD OF MAKING, AND USE AS BTK INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | claimed |
| EP-2297105-B1 | SUBSTITUTED AMIDES, METHOD OF MAKING, AND USE AS BTK INHIBITORS | GILEAD CONNECTICUT INC (US) | 2015-09-02 | — | — | EP | disclosed |
| US-8426424-B2 | Certain substituted amides, method of making, and method of use thereof | CGI PHARMACEUTICALS, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-20110118233-A1 | Certain Substituted Amides, Method of Making, and Method of Use Thereof | CGI PHARMACEUTICALS, INC. | 2011-05-19 | — | — | US | disclosed |
| EP-2297105-A1 | SUBSTITUTED AMIDES, METHOD OF MAKING, AND USE AS BTK INHIBITORS | CGI Pharmaceuticals, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118233-A1 | Certain Substituted Amides, Method of Making, and Method of Use Thereof | BTK, SYK, MYD88 | BTK 1/4885CD69 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.